Wei S, Deng Y, Lee J, Lan H, Yang Z, Labrie M, Betts CB, Duan H, Tate B, Pucilowska J, Frederick D, Lawless AR, Sharova T, Yang Y, Hu W, Beasley GM, Schuchter LM, Wang X, Xu W, Yong G, Vandenberg MEG, Torigian DA, Sivagnanam S, Du K, Sugarman E, McGettigan S, Zheng C, Al-Rohil RN, Selim MA, Datto MB, López GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O’Rourke DM, Brem S, O’Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Mou Y, Flaherty KT, Coussens LM, Boland G, Herlyn M, Mills G, Liu L, Zhang G. A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell Reports Medicine. 2026;7(4):10.1016/j.xcrm.2026.102716
Barnwal A, Yan W, Cook SL, Urup T, Stevenson K, He Y, Osorio C, Parker S, Edouard E, Bowie M, Jackson HC, McLendon RE, Desjardins A, Ashley DM, Bigner DD, Chandramohan V. Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma. 2026;:10.21203/rs.3.rs-9350019/v1
Owens E, Hotchkiss K, Threatt S, Low JT, Anand M, Louw J, Goldston M, Johnson MO, Bradbury C, Herndon JE, Grant GA, Ashley DM, Patel AP, Desjardins A, Brown MC, Khasraw M. Abstract 7769: IL-12/anti-PD-1 armored oncolytic HSV-1 reprograms CNS immunity: Integrated longitudinal immune, genomic, and metabolic CSF profiling in the MVR-C5252 PuMP Trial. Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-7769
Benz MC, Zhang K, Ashley DM, Garde C, Singh K, Rasmus OA, Rønø B, Kleine-Kohlbrecher D, Thorsen SF, Hotchkiss KM, Conejo-Garcia JR, Khasraw M. Abstract 6975: Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma. Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-6975
Owens E, Hotchkiss KM, Norberg P, Buckley E, Ayasoufi K, Threatt S, Low JT, Shoaf ML, Goldston M, Batich K, Johnson MO, Herndon JE, Nair SK, Weinhold K, Friedman HS, Ashley DM, Desjardins A, Sampson JH, Khasraw M. Abstract 6477: Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial. Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-6477
Louw J, Zhang K, Corcoran A, Owens E, Jepson J, Conejo-Garcia JR, Ashley DM, Mirchia K, Raleigh DR, Khasraw M. Abstract 6212: Spatial immune and vascular remodeling defines recurrence in oligodendroglioma. Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-6212
Gregory SG, Whaley-Powers L, Jain V, Aksu M, Hocke E, Smith A, Arvai S, Haukefrers E, Stevenson K, Patel K, Satterfield D, Thomas E, Abramson K, Lopez GY, McLendon RE, Ashley DM. Abstract 1997: Integrative single-nuclei spatial transcriptomic profiling of primary and recurrent human glioblastoma reveals cell-specific EGFRvIII expression and ANXA1 signaling axis.Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-1997
Brown A, Strickland LM, Erman EN, Pirozzi CJ, Low JT, Diplas BH, Gibson E, Shobande M, Khambati T, Krylova M, Liu H, McLendon RE, Reitman ZJ, Keir ST, Zou L, Ashley DM, Waitkus MS. SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres. Neuro-Oncology. 2026;28(4):10.1093/neuonc/noaf300
Ouyang S, Wertman V, Bowie M, Waitkus M, López G, Low J, Ashley D. Abstract A010: Epigenetic priming restores tumor-intrinsic cGAS–STING competence in glioblastoma and enables immunogenic DNA damage responses. Cancer Research. 2026;86(6_Supplement):10.1158/1538-7445.brain26-a010
Ouyang S, Wertman V, Brown M, Waitkus M, Low J, Ashley D. Abstract A003: Chronic cGAS–STING activation reprograms glioblastoma-associated macrophages toward immunosuppression in hypoxic tumor niches. Cancer Research. 2026;86(6_Supplement):10.1158/1538-7445.brain26-a003
